These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 22134572

  • 1. Erythema multiforme-like drug reaction to sorafenib.
    Lewin J, Farley-Loftus R, Pomeranz MK.
    J Drugs Dermatol; 2011 Dec; 10(12):1462-3. PubMed ID: 22134572
    [Abstract] [Full Text] [Related]

  • 2. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
    McLellan B, Kerr H.
    Dermatol Ther; 2011 Dec; 24(4):396-400. PubMed ID: 21910797
    [Abstract] [Full Text] [Related]

  • 3. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK.
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [Abstract] [Full Text] [Related]

  • 4. [Hand-foot syndrome and sorafenib].
    Milano G, Mortier L, Digue L, Desmedt E, Ravaud A.
    Bull Cancer; 2009 Feb; 96(2):191-7. PubMed ID: 19258226
    [Abstract] [Full Text] [Related]

  • 5. Interstitial granulomatous drug reaction to sorafenib.
    Martínez-Morán C, Nájera L, Ruiz-Casado AI, Romero-Maté A, Espinosa P, Meseguer-Yebra C, Córdoba S, Borbujo JM.
    Arch Dermatol; 2011 Sep; 147(9):1118-9. PubMed ID: 21931061
    [No Abstract] [Full Text] [Related]

  • 6. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
    Lipworth AD, Robert C, Zhu AX.
    Oncology; 2009 Sep; 77(5):257-71. PubMed ID: 19923864
    [Abstract] [Full Text] [Related]

  • 7. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
    Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, Kuo TT, Hsieh JJ, Chang JW.
    Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
    [Abstract] [Full Text] [Related]

  • 8. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J, Escudier B, Wechsler J, Spatz A, Robert C.
    Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
    [Abstract] [Full Text] [Related]

  • 9. [Hand-foot syndrome after administration of tyrosinkinase inhibitors].
    Bednaríková D, Kocák I.
    Klin Onkol; 2010 Jul; 23(5):300-5. PubMed ID: 21061680
    [Abstract] [Full Text] [Related]

  • 10. Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction.
    Jain L, Gardner ER, Figg WD, Chernick MS, Kong HH.
    Pharmacotherapy; 2010 Jan; 30(1):52-6. PubMed ID: 20030473
    [Abstract] [Full Text] [Related]

  • 11. Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib.
    Wolber C, Udvardi A, Tatzreiter G, Schneeberger A, Volc-Platzer B.
    J Dtsch Dermatol Ges; 2009 May; 7(5):449-52. PubMed ID: 19178612
    [Abstract] [Full Text] [Related]

  • 12. Erythema multiforme induced by sorafenib.
    Feltes RA, Feito Rodríguez M, González-Beato MJ.
    Clin Exp Dermatol; 2009 Oct; 34(7):e368-9. PubMed ID: 19489856
    [No Abstract] [Full Text] [Related]

  • 13. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
    Bukowski RM.
    Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
    [No Abstract] [Full Text] [Related]

  • 14. Sorafenib-induced erythema multiforme: three cases.
    Namba M, Tsunemi Y, Kawashima M.
    Eur J Dermatol; 2011 Jan; 21(6):1015-6. PubMed ID: 21926043
    [No Abstract] [Full Text] [Related]

  • 15. [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
    Wollenberg A, Staehler M, Eames T.
    Hautarzt; 2010 Aug; 61(8):662-7. PubMed ID: 20631979
    [Abstract] [Full Text] [Related]

  • 16. Severe sorafenib-induced hand-foot skin reaction.
    Cuesta L, Betlloch I, Toledo F, Latorre N, Monteagudo A.
    Dermatol Online J; 2011 May 15; 17(5):14. PubMed ID: 21635836
    [Abstract] [Full Text] [Related]

  • 17. [Cutaneous side effects of sorafenib and sunitinib].
    Autier J, Mateus C, Wechsler J, Spatz A, Robert C.
    Ann Dermatol Venereol; 2008 Feb 15; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
    [No Abstract] [Full Text] [Related]

  • 18. Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
    Kodaira M, Takahashi S, Takeuchi K, Yuasa T, Saotome T, Yonese J, Fukui I, Hatake K.
    Ann Oncol; 2010 Jul 15; 21(7):1563-1565. PubMed ID: 20573851
    [No Abstract] [Full Text] [Related]

  • 19. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.
    Am J Clin Oncol; 2010 Jun 15; 33(3):217-20. PubMed ID: 19745694
    [Abstract] [Full Text] [Related]

  • 20. Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
    Ikeda M, Fujita T, Mii S, Tanabe K, Tabata K, Matsumoto K, Satoh T, Iwamura M.
    Jpn J Clin Oncol; 2012 Sep 15; 42(9):820-4. PubMed ID: 22782962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.